

Jean François Emile

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5302446/publications.pdf>

Version: 2024-02-01

188
papers

13,992
citations

31976

53
h-index

22166

113
g-index

196
all docs

196
docs citations

196
times ranked

12834
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>KRAS</i> Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. <i>Journal of Clinical Oncology</i> , 2008, 26, 374-379.	1.6	1,398
2	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. <i>Leukemia</i> , 2022, 36, 1703-1719.	7.2	1,211
3	Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. <i>Blood</i> , 2016, 127, 2672-2681.	1.4	1,040
4	Consensus meeting for the management of gastrointestinal stromal tumors— Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. <i>Annals of Oncology</i> , 2005, 16, 566-578.	1.2	628
5	High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. <i>Blood</i> , 2012, 120, 2700-2703.	1.4	589
6	Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. <i>Blood</i> , 2013, 121, 1495-1500.	1.4	479
7	Langerhans cell histiocytosis in adults Report from the International Registry of the Histiocyte Society. <i>European Journal of Cancer</i> , 2003, 39, 2341-2348.	2.8	450
8	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Cancer Discovery</i> , 2016, 6, 154-165.	9.4	372
9	Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-DeStombes disease. <i>Blood</i> , 2018, 131, 2877-2890.	1.4	335
10	Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 862-873.	10.7	239
11	Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With <i>BRAF</i> ^{V600E} -Mutated Erdheim-Chester Disease. <i>Journal of Clinical Oncology</i> , 2015, 33, 411-418.	1.6	238
12	<i>BRAF</i> Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. <i>Journal of Clinical Oncology</i> , 2016, 34, 3023-3030.	1.6	233
13	Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma. <i>Gastroenterology</i> , 2012, 143, 664-674.e6.	1.3	218
14	Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. <i>Blood</i> , 2014, 124, 1119-1126.	1.4	208
15	Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. <i>Blood</i> , 2014, 124, 3016-3019.	1.4	197
16	Pangenomic Classification of Pituitary Neuroendocrine Tumors. <i>Cancer Cell</i> , 2020, 37, 123-134.e5.	16.8	186
17	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, 771-781.	10.7	167
18	Histiocytoses: emerging neoplasia behind inflammation. <i>Lancet Oncology</i> , The, 2017, 18, e113-e125.	10.7	154

#	ARTICLE	IF	CITATIONS
19	Human IFN- γ immunity to mycobacteria is governed by both IL-12 and IL-23. <i>Science Immunology</i> , 2018, 3, .	11.9	152
20	Definitive Diagnosis with the Use of Monoclonal Antibody O10 on Routinely Paraffin-embedded Samples. <i>American Journal of Surgical Pathology</i> , 1995, 19, 636-641.	3.7	148
21	Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). <i>Blood</i> , 2017, 130, 1377-1380.	1.4	146
22	Detection of BRAF p.V600E Mutations in Melanomas. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 94-100.	2.8	144
23	Clinical Relevance of <i>KRAS</i> -Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 1087-1097.	7.0	137
24	B-RAF Mutant Alleles Associated with Langerhans Cell Histiocytosis, a Granulomatous Pediatric Disease. <i>PLoS ONE</i> , 2012, 7, e33891.	2.5	132
25	Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2857-2865.	1.6	132
26	Prognostic Effect of <i>BRAF</i> and <i>KRAS</i> Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab. <i>JAMA Oncology</i> , 2016, 2, 643.	7.1	125
27	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. <i>Nature Medicine</i> , 2019, 25, 1839-1842.	30.7	122
28	Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab. <i>Oncotimmunology</i> , 2018, 7, e1452581.	4.6	115
29	A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker. <i>Clinical Chemistry</i> , 2016, 62, 1129-1139.	3.2	111
30	Erdheim-Chester Disease. <i>Current Rheumatology Reports</i> , 2014, 16, 412.	4.7	110
31	Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. <i>Experimental and Molecular Pathology</i> , 2012, 92, 275-280.	2.1	106
32	Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. <i>Annals of Oncology</i> , 2020, 31, 921-929.	1.2	104
33	Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. <i>Blood</i> , 2017, 130, 176-180.	1.4	98
34	High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. <i>Blood</i> , 2017, 130, 1007-1013.	1.4	98
35	Phenotypes and survival in Erdheim-Chester disease: Results from a 165 patient cohort. <i>American Journal of Hematology</i> , 2018, 93, E114-E117.	4.1	94
36	Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis. <i>JAMA Oncology</i> , 2015, 1, 836.	7.1	92

#	ARTICLE	IF	CITATIONS
37	Prognostic Value of BRAF V600 Mutations in Melanoma Patients After Resection of Metastatic Lymph Nodes. <i>Annals of Surgical Oncology</i> , 2012, 19, 4314-4321.	1.5	91
38	FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. <i>Blood</i> , 2017, 130, 1315-1326.	1.4	87
39	Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. <i>British Journal of Haematology</i> , 2016, 174, 887-898.	2.5	83
40	Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 597-605.	4.4	82
41	Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study. <i>Gut</i> , 2020, 69, 681-690.	12.1	79
42	Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy. <i>Clinical Cancer Research</i> , 2011, 17, 7470-7478.	7.0	76
43	Dramatic response of a <i>BRAF</i> V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. <i>Neurology</i> , 2014, 83, 1478-1480.	1.1	70
44	Inherited IL-18BP deficiency in human fulminant viral hepatitis. <i>Journal of Experimental Medicine</i> , 2019, 216, 1777-1790.	8.5	70
45	Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial. <i>Blood</i> , 2015, 126, 1163-1171.	1.4	69
46	Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer. <i>Oncotarget</i> , 2018, 7, e1424675.	4.6	66
47	<i>BRAF</i> Mutations in Erdheim-Chester Disease. <i>Journal of Clinical Oncology</i> , 2013, 31, 398-398.	1.6	65
48	Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. <i>Nature Medicine</i> , 2021, 27, 1646-1654.	30.7	65
49	Cutaneous manifestations of Erdheim-Chester disease (ECD): Clinical, pathological, and molecular features in a monocentric series of 40 patients. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 513-520.	1.2	64
50	Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 1215-1224.	7.0	63
51	Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab. <i>Journal of Clinical Investigation</i> , 2019, 129, 176.		62
52	ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. <i>Blood</i> , 2022, 139, 256-280.	1.4	60
53	Association of IL-36 β with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 109-120.	4.2	59
54	Histiocytosis. <i>Lancet</i> , 2021, 398, 157-170.	13.7	58

#	ARTICLE	IF	CITATIONS
55	Detection of <i>BRAF</i> V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 71-75.	2.5	57
56	Circulating cell-free <i>BRAF</i> V600E as a biomarker in children with Langerhans cell histiocytosis. <i>British Journal of Haematology</i> , 2017, 178, 457-467.	2.5	57
57	Efficacy of the <i>MEK</i> inhibitor cobimetinib for wild-type <i>BRAF</i> Erdheim-Chester disease. <i>British Journal of Haematology</i> , 2018, 180, 150-153.	2.5	55
58	Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With <i>RAS</i> and <i>BRAF</i> Mutational Status. <i>JAMA Oncology</i> , 2018, 4, e173695.	7.1	55
59	Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study. <i>British Journal of Haematology</i> , 2018, 183, 608-617.	2.5	54
60	A Mild Form of SLC29A3 Disorder: A Frameshift Deletion Leads to the Paradoxical Translation of an Otherwise Noncoding mRNA Splice Variant. <i>PLoS ONE</i> , 2012, 7, e29708.	2.5	50
61	Gastrointestinal stromal tumours (GISTs): French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). <i>Digestive and Liver Disease</i> , 2019, 51, 1223-1231.	0.9	49
62	Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 Td (Destination) <i>Oncology Reports</i> , 2019, 21, 62.	4.0	48
63	<i>BRAF</i> V600E Mutation in a Histiocytic Sarcoma Arising From Hairy Cell Leukemia. <i>Journal of Clinical Oncology</i> , 2014, 32, e117-e121.	1.6	47
64	Langerhans cell histiocytosis of the liver in adults. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 475-481.	1.5	46
65	<i>BRAF</i> V600E mutation detected in a case of Rosai-Dorfman disease. <i>Haematologica</i> , 2018, 103, e377-e379.	3.5	45
66	Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13. <i>European Journal of Cancer</i> , 2013, 49, 2531-2541.	2.8	41
67	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. <i>European Journal of Cancer</i> , 2017, 82, 16-24.	2.8	40
68	Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR). <i>Journal of Clinical Oncology</i> , 2020, 38, 1702-1710.	1.6	40
69	Complete remission of critical neurohistiocytosis by vemurafenib. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e78.	6.0	38
70	The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 1033-1042.	3.0	38
71	Adjuvant FOLFOX + cetuximab in full-RAS and BRAF wildtype stage III colon cancer patients. <i>Annals of Oncology</i> , 2017, 28, 824-830.	1.2	38
72	Erdheim-Chester Disease: a Concise Review. <i>Current Rheumatology Reports</i> , 2019, 21, 66.	4.7	38

#	ARTICLE	IF	CITATIONS
73	Fatal Cytomegalovirus Infection in an Adult with Inherited NOS2 Deficiency. <i>New England Journal of Medicine</i> , 2020, 382, 437-445.	27.0	38
74	Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 786-793.	1.2	37
75	New somatic BRAF splicing mutation in Langerhans cell histiocytosis. <i>Molecular Cancer</i> , 2017, 16, 115.	19.2	37
76	Variations of BRAF mutant allele percentage in melanomas. <i>BMC Cancer</i> , 2015, 15, 497.	2.6	36
77	Local immunomodulation combined to radiofrequency ablation results in a complete cure of local and distant colorectal carcinoma. <i>Oncolimmunology</i> , 2019, 8, 1550342.	4.6	36
78	Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by <i>MAP2K1</i> . <i>Haematologica</i> , 2020, 105, e5-e8.	3.5	34
79	Histiocytosis and the nervous system: from diagnosis to targeted therapies. <i>Neuro-Oncology</i> , 2021, 23, 1433-1446.	1.2	33
80	ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy. <i>Journal of Cancer</i> , 2014, 5, 425-432.	2.5	30
81	High frequency of clonal hematopoiesis in Erdheim-Chester disease. <i>Blood</i> , 2021, 137, 485-492.	1.4	30
82	High expression of both mutant and wild-type alleles of c-kit in gastrointestinal stromal tumors. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2004, 1688, 250-256.	3.8	29
83	Marked efficacy of vemurafenib in suprasellar Erdheim-Chester disease. <i>Neurology</i> , 2014, 83, 1294-1296.	1.1	29
84	Length Analysis of Polymerase Chain Reaction Products: A Sensitive and Reliable Technique for the Detection of Mutations in KIT Exon 11 in Gastrointestinal Stromal Tumors. <i>Diagnostic Molecular Pathology</i> , 2002, 11, 107-112.	2.1	28
85	Linear quantification of lymphoid infiltration of the tumor margin: a reproducible method, developed with colorectal cancer tissues, for assessing a highly variable prognostic factor. <i>Diagnostic Pathology</i> , 2012, 7, 156.	2.0	28
86	Common cancer-associated PIK3CA activating mutations rarely occur in Langerhans cell histiocytosis. <i>Blood</i> , 2015, 125, 2448-2449.	1.4	28
87	Highly sensitive methods are required to detect mutations in histiocytoses. <i>Haematologica</i> , 2019, 104, e97-e99.	3.5	27
88	Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?. <i>Cancers</i> , 2019, 11, 1269.	3.7	25
89	Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4768-4780.	7.0	25
90	The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. <i>EBioMedicine</i> , 2019, 46, 94-104.	6.1	24

#	ARTICLE	IF	CITATIONS
91	Progress towards molecular-based management of childhood Langerhans cell histiocytosis. Archives De Pediatrie, 2019, 26, 301-307.	1.0	24
92	Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression. , 2020, 8, e000527.		24
93	Clinical utility of colon cancer molecular subtypes: Validation of two main colorectal molecular classifications on the PETACC-8 phase III trial cohort.. Journal of Clinical Oncology, 2017, 35, 3509-3509.	1.6	24
94	Detection of BRAF V600 Mutations in Melanoma: Evaluation of Concordance between the Cobas® 4800 BRAF V600 Mutation Test and the Methods Used in French National Cancer Institute (INCa) Platforms in a Real-Life Setting. PLoS ONE, 2015, 10, e0120232.	2.5	24
95	Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). European Journal of Cancer, 2021, 159, 24-33.	2.8	24
96	Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide Experience. PLoS ONE, 2013, 8, e68945.	2.5	23
97	Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer. Journal of Molecular Diagnostics, 2016, 18, 205-214.	2.8	23
98	hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status. Cancers, 2019, 11, 1808.	3.7	23
99	Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis. Journal of the American Academy of Dermatology, 2015, 73, e29-e30.	1.2	22
100	Efficacy of infliximab in the treatment of Erdheim-Chester disease. Annals of the Rheumatic Diseases, 2018, 77, 1387-1390.	0.9	22
101	Central nervous system involvement in Erdheim-Chester disease. Neurology, 2020, 95, e2746-e2754.	1.1	22
102	Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: Towards the paradigm of combined targeting and immune therapies. Acta Oncologica, 2016, 55, 930-932.	1.8	19
103	Variation of mutant allele frequency in NRAS Q61 mutated melanomas. BMC Dermatology, 2017, 17, 9.	2.1	19
104	Contribution of genetic amplification by PCR for the diagnosis of <i>Helicobacter pylori</i> infection in patients receiving proton pump inhibitors. United European Gastroenterology Journal, 2018, 6, 1267-1273.	3.8	19
105	Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study. British Journal of Cancer, 2019, 120, 697-702.	6.4	19
106	Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA: The CIRCULATE-PRODIGE 70 trial. Digestive and Liver Disease, 2020, 52, 730-733.	0.9	18
107	Lung Involvement in Destombes-Rosai-Dorfman Disease. Chest, 2020, 157, 323-333.	0.8	17
108	Erdheim-Chester disease associated with chronic myelomonocytic leukemia harboring the same clonal mutation. Haematologica, 2019, 104, e530-e533.	3.5	16

#	ARTICLE	IF	CITATIONS
109	Baseline Hedgehog Pathway Activation and Increase of Plasma Wnt1 Protein Are Associated with Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 1107.	3.7	16
110	Hypoalbuminemia and BRAF ^{V600E} Mutation Are Major Predictors of Aortic Infiltration in the Erdheim-Chester Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1913-1925.	2.4	15
111	Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors. <i>Haematologica</i> , 2019, 104, e502-e505.	3.5	15
112	Congenital Neutropenia Is Also Associated with a High Cancer Risk: A Study from the French Severe Chronic Neutropenia Registry. <i>Blood</i> , 2020, 136, 15-16.	1.4	15
113	Childhood pulmonary Langerhans cell histiocytosis: a comprehensive clinical-histopathological and BRAFV600E mutation study from the French national cohort. <i>Human Pathology</i> , 2019, 89, 51-61.	2.0	14
114	Long-term follow-up of children with risk organ-negative Langerhans cell histiocytosis after 2-mercaptoethanol treatment. <i>British Journal of Haematology</i> , 2020, 191, 825-834.	2.5	14
115	Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. <i>Digestive and Liver Disease</i> , 2021, 53, 318-323.	0.9	14
116	Cutaneous histiocytoses in children. <i>Histopathology</i> , 2022, 80, 196-215.	2.9	14
117	GIST with homozygous KIT exon 11 mutations. <i>Laboratory Investigation</i> , 2008, 88, 456-457.	3.7	13
118	Copy-neutral loss of heterozygosity and chromosome gains and losses are frequent in gastrointestinal stromal tumors. <i>Molecular Cancer</i> , 2014, 13, 246.	19.2	12
119	Langerhans Cell Histiocytoma: A Benign Histiocytic Neoplasm of Diverse Lines of Terminal Differentiation. <i>American Journal of Dermatopathology</i> , 2019, 41, 29-36.	0.6	12
120	Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4) Tj ETQq0 0 DrgBT /Overlock 10		
121	Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group. <i>BMC Cancer</i> , 2013, 13, 472.	2.6	11
122	CARMN-NOTCH2 fusion transcript drives high NOTCH2 expression in glomus tumors of the upper digestive tract. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 723-732.	2.8	11
123	Diagnostic criteria, specific mutations, and genetic predisposition in gastrointestinal stromal tumors. <i>The Application of Clinical Genetics</i> , 2010, 3, 85.	3.0	10
124	Clinical Cutaneous Features of Patients Infected With SARS-CoV-2 Hospitalized for Pneumonia: A Cross-sectional Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa394.	0.9	10
125	Pancreatic Ductal Adenocarcinoma Arising in Young and Old Patients Displays Similar Molecular Features. <i>Cancers</i> , 2021, 13, 1234.	3.7	10
126	Effects of endoplasmic reticulum stressors on maturation and signaling of hemizygous and heterozygous wild-type and mutant forms of KIT. <i>Molecular Oncology</i> , 2013, 7, 323-333.	4.6	9

#	ARTICLE	IF	CITATIONS
127	Identification of precancerous lesions by multispectral gastroendoscopy. <i>Signal, Image and Video Processing</i> , 2016, 10, 455-462.	2.7	9
128	Gene Expression Patterns of Hemizygous and Heterozygous KIT Mutations Suggest Distinct Oncogenic Pathways: A Study in NIH3T3 Cell Lines and GIST Samples. <i>PLoS ONE</i> , 2013, 8, e61103.	2.5	9
129	Increase in NRAS mutant allele percentage during metastatic melanoma progression. <i>Experimental Dermatology</i> , 2016, 25, 472-474.	2.9	8
130	Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR). <i>Journal of Clinical Oncology</i> , 2019, 37, 3513-3513.	1.6	8
131	<i>CDKN2A</i> Depletion Causes Aneuploidy and Enhances Cell Proliferation in Non-Immortalized Normal Human Cells. <i>Cancer Investigation</i> , 2018, 36, 338-348.	1.3	7
132	Tumour and stroma RNA signatures predict more accurately distant recurrence than clinicopathological factors in resected pancreatic adenocarcinoma. <i>European Journal of Cancer</i> , 2021, 148, 171-180.	2.8	7
133	Prognostic Value of <i>Fusobacterium nucleatum</i> after Abdominoperineal Resection for Anal Squamous Cell Carcinoma. <i>Cancers</i> , 2022, 14, 1606.	3.7	7
134	Immune phenotyping of Erdheim-Chester disease through mass cytometry highlights decreased proportion of non-classical monocytes and increased proportion of Th17 cells. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1522-1524.	0.9	6
135	Plasma Biomarkers Screening by Multiplex ELISA Assay in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 97.	3.7	6
136	Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration. <i>Oncotarget</i> , 2017, 8, 109818-109835.	1.8	5
137	The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim-Chester Disease. <i>Cancers</i> , 2020, 12, 3240.	3.7	5
138	A circulating subset of <i>BRAF</i> ^{V600E} -positive cells in infants with high-risk Langerhans cell histiocytosis treated with BRAF inhibitors. <i>British Journal of Haematology</i> , 2021, 194, 745-749.	2.5	5
139	Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCO 1703-POCHI trial. <i>Digestive and Liver Disease</i> , 2021, 53, 1254-1259.	0.9	5
140	Sacroiliitis in a patient with Rosai-Dorfman disease: new bone location or overlap with axial spondylarthritis?. <i>Rheumatology</i> , 2020, 59, 2168-2170.	1.9	4
141	Shwachman-Diamond syndrome and solid tumors: Three new patients from the French Registry for Severe Chronic Neutropenia and literature review. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29071.	1.5	4
142	Loss of SMARCB1 expression in colon carcinoma. <i>Cancer Biomarkers</i> , 2020, 27, 399-406.	1.7	4
143	Reply to "Clinical and therapeutic implications of <i>BRAF</i> mutation heterogeneity in metastatic melanoma" by Mesbah Ardakani et al.. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 498-500.	3.3	3
144	Multispectral imaging detects gastritis consistently in mouse model and in humans. <i>Scientific Reports</i> , 2020, 10, 20047.	3.3	3

#	ARTICLE	IF	CITATIONS
145	Refractory Inflammatory Bowel Disease Associated With Sclerosing Cholangitis, Diabetes Insipidus, and Myeloid Neoplasm: Langerhans Cell Histiocytosis Was Hiding Since the Beginning. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e85-e86.	1.9	3
146	Peritoneal or mesenteric tumours revealing histiocytosis. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000622.	2.7	3
147	Immune Thrombocytopenia Revealing Enriched IgG-4 Peri-Renal Rosai-Dorfman Disease Successfully Treated with Rituximab: A Case Report and Literature Review.. <i>Frontiers in Medicine</i> , 2021, 8, 678456.	2.6	3
148	Frequent Clinical Overlap of Histiocytic Neoplasms and WHO-Classified Myeloid Malignancies Leads to Functional Insights into the Cell-of-Origin of Histiocytoses. <i>Blood</i> , 2016, 128, 951-951.	1.4	3
149	Validation of the prognostic impact of lymphocyte infiltration (LI) in patients (pts) with stage III colon cancer (CC) treated with adjuvant FOLFOX+/- cetuximab: A PETACC8 translational study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 553-553.	1.6	3
150	Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3515-3515.	1.6	3
151	Improvement of immune response after radiofrequency ablation in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 102-102.	1.6	3
152	MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis. <i>Leukemia</i> , 2021, . .	7.2	3
153	High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors. <i>Frontiers in Oncology</i> , 2021, 11, 747692.	2.8	3
154	Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2791-2799.	4.2	3
155	Malignant Histiocytosis With PD-L1 Expressionâ€”Dramatic Response to Nivolumab. <i>Mayo Clinic Proceedings</i> , 2022, 97, 1401-1403.	3.0	3
156	Neurodegeneration in histiocytoses might start in utero. <i>Lancet Neurology</i> , The, 2017, 16, 953-954.	10.2	2
157	Response to trametinib of histiocytosis with an activating <i>PTPN11</i> mutation. <i>Leukemia and Lymphoma</i> , 2020, 61, 194-197.	1.3	2
158	High Serum VEGF Level in Erdheim-Chester Disease: Correlation with Cardiovascular Involvement and Response to Treatment. <i>Blood</i> , 2019, 134, 2324-2324.	1.4	2
159	Impact of mutational status and other prognostic factors on survival in patients with advanced GIST treated with standard-dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10548-10548.	1.6	2
160	Correlation of BRAF V600E mutation with cardiac involvement assessed by heart imaging in a monocentric series of 205 patients with Erdheim-Chester disease.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7019-7019.	1.6	2
161	Case Report: Evolution of a Severe Vascular Refractory Form of ECD Requiring Liver Transplantation Correlated With the Change in the Monocyte Subset Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 755846.	4.8	2
162	Second primary cutaneous melanoma in patients with advanced melanoma treated with antiâ€”programmedâ€”deathâ€”receptorâ€”1 monoclonal antibodies. <i>British Journal of Dermatology</i> , 2021, 184, 746-748.	1.5	1

#	ARTICLE	IF	CITATIONS
163	Prognostic value of <i>BRAF</i> ^{V600} mutations in American Joint Committee on Cancer (AJCC) stage 3 cutaneous melanoma patients in the MelanCohort prospective cohort.. Journal of Clinical Oncology, 2015, 33, 9037-9037.	1.6	1
164	Histology of Rosai-Dorfman disease in a subset of patients with Erdheim-Chester disease: A distinct entity mainly driven by MAP2K1.. Journal of Clinical Oncology, 2018, 36, e24180-e24180.	1.6	1
165	Prognostic value of BRAFV600 mutations in melanoma patients after resection of metastatic lymph nodes.. Journal of Clinical Oncology, 2012, 30, 8540-8540.	1.6	1
166	Discontinuation of anti-PD-1 mAb after complete response in advanced melanoma pts.. Journal of Clinical Oncology, 2018, 36, e21549-e21549.	1.6	1
167	Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (three versus six months) in the prospective IDEA France cohort study (PRODIGE-GERCOR).. Journal of Clinical Oncology, 2020, 38, 10-10.	1.6	1
168	Pediatric Erdheim-Chester Disease in the Molecular Era: A Multicenter Case Series. Blood, 2021, 138, 4194-4194.	1.4	1
169	Granulomatous splenic mass with necrosis revealing an EBV-positive inflammatory follicular dendritic cell sarcoma. Journal of Surgical Case Reports, 2022, 2022, rjac034.	0.4	1
170	Histiocytosis systémiques. EMC - Tratado De Medicina, 2017, 21, 1-4.	0.0	0
171	AB1144. Histology of rosai-dorfman disease in a subset of patients with erdheim-chester disease: a distinct entity mainly driven by map2k1. , 2018, , .		0
172	Histiocytoses. , 2018, , 379-390.		0
173	Atteintes ostéoarticulaires au cours des histiocytoses. Revue Du Rhumatisme Monographies, 2019, 86, 120-125.	0.0	0
174	IgG4-related disease and Rosai-Dorfman-Destombes disease " Authors' reply. Lancet, The, 2021, 398, 1214-1215.	13.7	0
175	miRNA expression as a predictor of survival in patients with metastatic colorectal cancer treated with EGFR inhibitors.. Journal of Clinical Oncology, 2012, 30, e14059-e14059.	1.6	0
176	Relationship of the topography of KIT exon 11 alterations and predictive value for PFS in patients with advanced GIST: Results of the BFR14 prospective French Sarcoma Group randomized phase III trial.. Journal of Clinical Oncology, 2013, 31, 10542-10542.	1.6	0
177	Prognostic value of <i>KRAS</i> exon 2 gene mutations in stage III colon cancer: Post hoc analyses of the PETACC8 trial.. Journal of Clinical Oncology, 2014, 32, 3549-3549.	1.6	0
178	Langerhans cell histiocytosis in children: Correlation of <i>BRAF</i> status with clinical characteristic.. Journal of Clinical Oncology, 2015, 33, 10003-10003.	1.6	0
179	Recurrent BRAF mutations in bone marrow progenitors of patients with Erdheim-Chester disease.. Journal of Clinical Oncology, 2016, 34, 7069-7069.	1.6	0
180	Frequent allelic imbalance in <i>NRAS</i> mutant melanomas.. Journal of Clinical Oncology, 2016, 34, 9578-9578.	1.6	0

#	ARTICLE	IF	CITATIONS
181	Treatment of Erdheim-Chester disease patients with the MEK inhibitor cobimetinib.. Journal of Clinical Oncology, 2016, 34, e19074-e19074.	1.6	0
182	PRODIGE 52-UCGI 29-CCTG/CO.27 (IROCAS): A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 TPS3622-TPS3622.	1.6	0
183	PD-1/ PD-L1 Expression Is Associated with Tissue Inflammation and BRAF Status in Erdheim-Chester Disease. Blood, 2018, 132, 4380-4380.	1.4	0
184	Prognostic value of tumor deposits for disease free survival in patients with stage III colon cancer: A post hoc analysis of IDEA France phase III trial (PRODIGE-GERCOR).. Journal of Clinical Oncology, 2019, 37, 3519-3519.	1.6	0
185	Molecular Characterisation of Diffuse Large B Cell Lymphoma in Patients of 80 Years Old or More: Clinical Relevance in a Multicentric Randomized Phase III Study of the Lysa (SENIOR Study). Blood, 2019, 134, 2765-2765.	1.4	0
186	Nationwide incidence of sarcomas and tumors of intermediate malignancy in the NETSARC network with central pathology review: Correlation with published clinical research.. Journal of Clinical Oncology, 2020, 38, 11560-11560.	1.6	0
187	Second primary melanoma in advanced melanoma patients treated with anti-PD-1 monoclonal antibodies.. Journal of Clinical Oncology, 2020, 38, e22025-e22025.	1.6	0
188	Malignant histiocytosis with a Langerhans cell subtype: A report on the diagnostic and therapeutic challenge. Blood Cells, Molecules, and Diseases, 2021, 92, 102623.	1.4	0